On November 12, Hangzhou Yili Pharmaceutical Co., Ltd. announced the completion of Series A financing of nearly 400 million yuan. This round of financing was led by Huagai Capital, co-led by Kangjun Capital, Boyu Venture Capital, German Union Capital, Xincheng Fund, Haibang Investment, Borui Capital, Shenzhen Angel, and Yuanyi Investment. The original shareholders Shiyao Guofang Pilot Fund, Weige Capital, Xineng Venture Capital, Longfeng Venture Capital, Hongsheng Capital, Shell Fund, and Honghou Investment continued to increase.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.